Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRD-4730 in Catecholaminergic Polymorphic Ventricular Tachycardia
NCT06005428Phase 2Terminated
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of CRD-4730 in catecholaminergic polymorphic ventricular tachycardia (CPVT), sponsored by Cardurion Pharmaceuticals. Started Nov 2023; status: terminated.
02
Drugs
CRD-4730
03
Conditions
catecholaminergic polymorphic ventricular tachycardia (CPVT)
Beyond the preview
Go deeper on NCT06005428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005428.